SNDX Q4 2019 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$380,000+0.0% YoY

Gross Profit

$380,000100.0% margin

Operating Income

-$14M-3738.2% margin

Net Income

-$14M-3684.2% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

+0.3%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$64M

Total Liabilities

$32M

Stockholders' Equity

$32M

Cash & Equivalents

$25M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$380,000	$380,000	+0.0%
Gross Profit	$380,000	$380,000	+0.0%
Operating Income	-$14M	-$19M	+26.5%
Net Income	-$14M	-$19M	+25.7%